Erin Cobain, MD

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.

Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.

Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.

Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.

A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.

Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.